The Carlyle Group agrees to invest in LPG Systems, manufacturer of non-surgical aesthetic and physiotherapy devices


Fresh capital will support international expansion and growth

Valence, France, 16 July 2018 – Global alternative asset manager The Carlyle Group (NASDAQ: CG) today announces that it has agreed to acquire a majority stake in LPG Systems (LPG), the specialist manufacturer of non-surgical aesthetic and physiotherapy devices, to support the company’s continued international expansion and growth trajectory. Equity for the transaction will come from Carlyle Europe Technology Partners III and Carlyle Asia Growth Partners V. The Guitay family will remain shareholders alongside Carlyle. The transaction is subject to customary regulatory approval and is expected to close by end of September this year.

Founded in 1986 by Louis-Paul Guitay, LPG has developed a non-surgical technology that serves the global medical, physiotherapy and aesthetics markets. The company’s technology enables physicians to provide advanced solutions for a broad range of medical, therapeutic and aesthetic applications including body contouring, cellulite and fat reduction, facial rejuvenation, burn treatment, scars reduction, lymphatic drainage and neuro physical training. Physiotherapists, medical clinics as well as Spas and luxury hotels in more than 100 countries currently use LPG devices.

Key to LPG’s success is its unique, patented technology, based on cells stimulation called Endermologie®. It is a treatment that the company has developed in close collaboration with scientists and practitioners, and is widely recognized by more than 140 scientific studies and 80 medical publications. LPG’s product portfolio is designed around the concept of well-being, offering a balance between efficiency and natural, painless treatments.

Nathalie Guitay, Chair of LPG, said: “Carlyle’s investment is testament to the strength of LPG’s product portfolio and our unparalleled technology. For more than 30 years, we have invested in R&D to develop non-surgical devices with wide-ranging applications that are suitable for our customers and patients. With the support of Carlyle, and drawing on its experience in international healthcare and consumer markets, we believe we are well positioned to further grow LPG’s international presence and to broaden our customer base whilst enhancing our product portfolio and the application of our devices.”

Vladimir Lasocki, Managing Director and co-Head of the Carlyle Europe Technology Partners team, said: “LPG is a business with strong brand recognition and an incredible reputation among both medical practitioners and end customers. LPG has successfully expanded the use of its technology across a broad range of physiotherapeutic and medical-aesthetic applications, and today they are well positioned to take advantage of the rising demand for non-surgical, natural treatments.”

Ling Yang, Managing Director of the Carlyle Asia Partners team, added: “We believe there is a great opportunity to further expand LPG’s business in Asia, particularly in China and Japan, through Carlyle’s local presence. We look forward to partnering with LPG’s management team as the company continues to grow and innovate.”


About LPG Systems

For 30 years, LPG has been developing, manufacturing and marketing patented advanced technologies for the medical, physiotherapy, aesthetic and athletic markets worldwide. Endermologie® is the only 100% natural, non-invasive and non-aggressive technique that exist today. It mechanically stimulates the cells to naturally revive and rejuvenate skin. It allows simultaneous treatment of fat reduction and body contouring.

About The Carlyle Group

The Carlyle Group (NASDAQ: CG) is a global alternative asset manager with $201 billion of assets under management across 324 investment vehicles as of March 31, 2018. Carlyle’s purpose is to invest wisely and create value on behalf of its investors, many of whom are public pensions. Carlyle invests across four segments – Corporate Private Equity, Real Assets, Global Credit and Investment Solutions – in Africa, Asia, Australia, Europe, the Middle East, North America and South America. Carlyle has expertise in various industries, including: aerospace, defense & government services, consumer & retail, energy, financial services, healthcare, industrial, real estate, technology & business services, telecommunications & media and transportation. The Carlyle Group employs more than 1,575 people in 31 offices across six continents.


About Carlyle Europe Technology Partners

Carlyle Europe Technology Partners (CETP) seeks to invest in European technology, media and telecommunications (TMT) companies. CETP’s European team of advisors provides strategic direction and resources to help accelerate the growth of companies in which CETP has invested and to support their efforts to expand internationally and to open up new market opportunities. The current fund is now the fourth one in the CETP franchise. In total, more than 143 investors from 34 countries have made commitments to CETP funds.

About Carlyle Asia

The Carlyle Asian private equity team (excluding Japan) has more than 50 investment professionals in eight offices, including Beijing, Hong Kong, Jakarta, Mumbai, Seoul, Shanghai, Singapore and Sydney. As of March 31, 2018, Carlyle’s Asian private equity platform has invested more than US$15 billion of equity, and currently has US$16.3 billion of assets under management.

In China, Carlyle has invested more than US$8 billion of equity in over 95 transactions as of March 31, 2018.

In Japan, Carlyle is the only global alternative asset manager to establish a dedicated Japan buyout fund denominated in yen. Carlyle’s Japan buyout funds, which have made 23 investments in Japan, have a track record of supporting Japanese mid-cap companies’ overseas business expansion, enhancing their operational efficiency and strengthening their management infrastructure.

Media Contacts

LPG Systems
Mandarine Basset

The Carlyle Group

Katarina Sallerfors
+44 (0)20 7894 3554

Brian Zhou
+86 10 57067070

Categories: News


Forbion exceeds target with EUR 270 million first close of its fourth life sciences VC fund


Investment focus will be on new drugs and technologies that will truly impact the future of medicine

Naarden, The Netherlands, and Munich, Germany, 11 July 2018 – Forbion, a leading European life science venture capital firm, has today announced the first close of its fourth flagship fund Forbion IV, at EUR 270 million, exceeding the EUR 250 million target size.

Forbion IV, like its predecessor fund, Forbion III, will primarily focus on EU and the UK (together c. 80% of investment), with the remainder of the fund targeting opportunities in North America.

Building on the successful Forbion III strategy, Forbion’s latest fund will have an even sharper focus on biotech. Forbion will also look to build on its proven ability to curate, initiate and transform investment ideas into standalone, high-return businesses, built around exciting new science, proven teams or assets sourced externally from Pharma. It will thus build a portfolio of approximately 15 companies, of which ten will be existing “growth” opportunities and five will be new companies (co-)founded by Forbion, so-called “build” opportunities.

The fourth fund will target substantial initial stakes of 20-50%, looking to take lead positions and work alongside entrepreneurial management teams to deliver exceptional returns as shown by Forbion’s highly successful third Fund (2015 vintage), which has already delivered three exits with several more in the making, including one near-term IPO.

Forbion has assembled a highly specialized and experienced team to manage the Fund, led by Sander Slootweg, Geert-Jan Mulder and Martien van Osch. The investment team are in turn supported by a high caliber group of operating partners, venture partners and advisers which affords Forbion exceptional reach and depth into its chosen markets.

A strong pipeline of investment opportunities has already been identified and the first close will facilitate Forbion’s discussion on these deals.

Forbion is targeting Autumn 2018 for the final close of Forbion IV.

Commenting, Sander Slootweg, Managing Partner, said:
“We have received exceptional support from both new and existing investors to reach the EUR 270 million first close. This is testament to the unrivalled experience and track record Forbion has built over many years of investing in European life sciences opportunities.

“The success of our first close not only reflects Forbion’s consistent delivery of upper quartile returns but also its clear vision and proprietary methodology for identifying new prospects. We continue to see the opportunities for superior returns, in part due to the ongoing undersupply of capital for European development-stage life sciences investment and its non-cyclical nature.

“Forbion will continue to benefit from its deep European and US/Canadian network and from its fundamental commercial understanding of the political, legal, regulatory and cultural dynamics at work across Europe; these factors contribute to our standing as an investor of choice in the European life sciences.

“We welcome our new investors and look forward to executing on our robust pipeline of opportunities and delivering continued outperformance.”

Categories: News


Breath Therapeutics Appoints Noreen Roth Henig, M.D. as Chief Medical Officer

GIlde Healthcare

Breath Therapeutics Appoints Noreen Roth Henig, M.D. as Chief Medical Officer

Dr. Henig adds leadership and development expertise in pulmonary disease, inhaled therapies, and orphan disease to the executive management team

Breath Therapeutics is targeting Bronchiolitis Obliterans with their first molecule, a Phase 3 ready asset

Munich, Frankfurt, Boston — Breath Therapeutics B.V. (Breath), a private company developing advanced drug-aerosol therapeutics in pulmonary orphan indications, announced today the appointment of Noreen Roth Henig, M.D. as Chief Medical Officer. Dr. Henig joins the executive management team and will lead Breath’s clinical development activities.

Dr. Henig brings to Breath more than 20 years of clinical and development leadership experience at emerging and leading biopharmaceutical companies, complemented by extensive medical experience in pulmonary and transplant medicine. Her expertise substantially strengthens BOSTON, the lead development program of inhaled L-CsA (Liposomal Cyclosporine A), for the treatment of Bronchiolitis Obliterans (BO), a lethal orphan respiratory disease. Breath’s pipeline of inhaled therapeutics is targeting severe respiratory diseases with high unmet medical need.

Noreen´s background in advanced lung disease and lung transplant, her senior drug development expertise, and her strong strategic corporate thinking is an outstanding combination and perfectly complements the Breath management team“, said Dr. Jens Stegemann, Chief Executive Officer of Breath Therapeutics.

Noreen Henig stated: “I am looking forward to joining the Breath Therapeutics team and to growing the young company. This is a unique opportunity to develop a promising Phase 3 ready asset for a true unmet medical need“.

Prior to joining Breath, Dr. Henig was CMO of ProQR Therapeutics, where she oversaw all preclinical and clinical development of candidate molecules and was also responsible for patient safety, data transparency, medical ethics and governance. She successfully led the young biotech company through organic growth and was instrumental in raising a pre-IPO series and a successful NASDAQ IPO for the then preclinical stage company. Previously, Dr. Henig served as Senior Director, Global Medical Affairs, Respiratory and PAH of Gilead Sciences, where she designed and executed clinical trials, up to Phase 4. In particular, she provided medical support to two therapies indicated for severe pulmonary disease. Throughout her career, Dr. Henig has held several senior academic positions related to respiratory diseases and lung transplant at the California Pacific Medical Center and the Stanford University School of Medicine. She earned her M.D. with Distinction in Immunology from the Albert Einstein College of Medicine, completed training in Internal Medicine at UCSF and Pulmonary and Critical Care Medicine at University of Washington, Seattle.


About Bronchiolitis Obliterans (BO)

Bronchiolitis Obliterans (BO) is a severe progressive orphan disease of the bronchioles of the lung that leads to death from respiratory failure. BO is the leading cause of loss of transplanted lungs. Of more than 25 000 people currently living with a lung transplant, approximately half will die within the next five years, mainly related to BO. BO also occurs in patients following allogeneic hematopoietic stem cell transplant, autoimmune disease and some environmental exposures.

About Breath Therapeutics

Breath is a clinical stage biopharmaceutical company specializing in advanced and first-in-class inhalation therapies for severe respiratory diseases with high unmet medical need. For its clinical development, the Company is using new proprietary drug formulations optimized for inhaled administration with exclusively licensed, high performance nebulizers. Breath is focusing on integrated therapy solutions in the interaction between diagnostics, therapeutics and eHealth therapy monitoring.

Breath´s lead development program BOSTON is addressing the treatment of BO with a proprietary formulation of liposomal cyclosporine for inhalation. With proceeds from a USD 46 million Series A financing by top-tier European investors Sofinnova, Gimv and Gilde Healthcare, the Company is currently initiating Phase 3 studies in the US and Europe. PARI Pharma, a worldwide leading nebulizer company, is a strategic development partner and licensor for the eFlow® nebulizer technology for Breath’s BOSTON program.

Breath Therapeutics is Germany and US based with offices in Frankfurt, Munich and Boston.

For more information, please visit


Breath Therapeutics B.V.
Dr. Jens Stegemann, CEO

Media inquiries:

MC Services AG
Dr. Claudia Gutjahr-Loeser, Managing Director
Tel. +49 89 210 228–0



Categories: Personalia


CapMan Buyout to sell InfoCare Group to Katalysator

Funds managed by CapMan Buyout have agreed to sell their holdings in InfoCare Group to the Norwegian private equity investment company Katalysator.

CapMan Buyout funds’ exit from portfolio company InfoCare Group (“InfoCare”) is already the sixth transaction within the last eight months.

InfoCare is one of the leading IT services companies in the Nordic countries. InfoCare’s services comprise field service, staffing services and spare parts logistics within the IT sector. In 2017 the net sales of InfoCare was approximately MEUR 90 and it employed a total of 870 persons.

“InfoCare is an undisputed market leader for more than 30 years in the Nordics and over the last years, the company has undergone a significant reorganization in terms of divestment of non-core business, new management, initiating cost efficiency programs and a new strategy for growth. InfoCare has a lot of potential to create stronger growth in existing and new business areas with the help of highly professional employees and satisfied top tier customers,” says Hanna Ideström, Investment Director at CapMan Buyout and responsible for the investment in InfoCare.

“We are very satisfied to have Katalysator as the new majority owner of InfoCare. Katalysator’s active and long-term investment perspective is important for us to realize our new strategy Skylift. With main focus on Customer Orientation, Operational Excellence and Growth we are going to lift InfoCare to new heights. Together with Katalysator and our fantastic employees, that is our most important asset, will we make this happen. I would like to thank CapMan for the continuous support during CapMan’s ownership,” says Kjell Magne Leirgulen, CEO of InfoCare.

“InfoCare has established a unique position in the Nordic market within IT services and we are very impressed by the management team. Katalysator will through active ownership support the management team and the development of the business, with strong customer focus, best practice operations and new growth initiatives. We see a significant potential for continued growth in the Nordics and look forward to work together with InfoCare’s employees in the coming years,” says Jon Håkon Pran, CEO of Katalysator.

Katalysator is a family owned investment company focusing on investments in medium-sized companies in Scandinavia. Katalysator currently has a portfolio of 6 companies and the team comprises 5 investment professionals.

The completion of the transaction is pending certain conditions including approval from competition authorities. Bridgehead acted as an advisor for CapMan Buyout in the transaction.

The CapMan Buyout team comprises 12 investment professionals working in Helsinki and Stockholm. The funds managed by CapMan Buyout invest in medium-sized, unlisted companies in the Nordic countries.

For more information, please contact:
Hanna Ideström, Investment Director, CapMan Buyout, tel. +46 705 861 348
Kjell Magne Leirgulen, CEO, InfoCare Group, tel. +47 97 72 31 21
Jon Håkon Pran, CEO, Katalysator, tel. +47 91 33 93 42


CapMan is a leading Nordic private asset expert with an active approach to value-creation in its target companies and assets. We offer a wide selection of investment products and services. As one of the Nordic private equity pioneers we have developed hundreds of companies and real estate and created substantial value in these businesses and assets over the last 28 years. CapMan has today approximately 120 private equity professionals and manages approximately €2.8 billion in assets under management. We mainly manage the assets of our customers, the investors, but also make investments from our own balance sheet. Our objective is to provide attractive returns and innovative solutions to investors. Our current investment strategies cover Real Estate, Buyout, Russia, Credit, Growth Equity and Infrastructure. We also have a growing service business that currently includes procurement services (CaPS), fundraising advisory (Scala Fund Advisory), and fund management services.


CVC Fund VII acquires controlling stake in Recordati S.p.A.

Andrea Recordati remains as CEO and invests alongside the consortium.

CVC is pleased to announce that a consortium of funds (the “Consortium”) led by CVC Fund VII has agreed to buy the holding company that owns a majority interest in Recordati.

Chairman Alberto Recordati said: “Today is an important moment in the further development of the company my grandfather founded over 90 years ago. We have found in CVC a partner who shares our vision, values and passion for the company, its employees and its role in developing and distributing healthcare around the world.”

Andrea Recordati, CEO, said: “I believe that this is a great outcome for the company and its employees who will benefit greatly from having CVC as a partner. In the process of finding the best partner to take Recordati forward, it was important to find a party that would allow Recordati to remain independent, with continuity for management and employees, and accelerate its growth strategy as a leading global consolidator in the pharmaceutical industry. I am very pleased to be working alongside CVC in accelerating Recordati’s global expansion. I am personally reinvesting alongside the Consortium as I believe in and support Recordati.”

Giampiero Mazza, Head of CVC Italy, said: “We are honoured to be chosen by the Recordati family who have put great trust in us to continue in their role as the majority shareholder of their company. We have a great admiration for the business which we have known for over many years since Giovanni Recordati was CEO. We are excited by the opportunity to support this excellent management team, led by Andrea Recordati who we have asked to remain as CEO and who carries on the company’s legacy and provides the continuity of the business and its strategy alongside Fritz Squindo, Recordati’s Managing Director and CFO.”

Cathrin Petty, Head of EMEA Healthcare at CVC, added: “Recordati has always been a very carefully managed, international pharma company with a broad platform of products and a strong geographical footprint in primary care. Over the last decade Recordati has built up a very attractive rare disease business which we look forward to expanding in addition to the core business. We hope that through our expertise and global healthcare network we will help accelerate this growth across orphan and specialty care to build a global leader in the industry.”

The transaction is structured as a fully financed acquisition by the Consortium of the family’s holding company FIMEI S.p.A for an Enterprise Value of €3.03bn. FIMEI owns 51.8% of Recordati S.p.A., implying a 100% equity value for Recordati S.p.A. of €5.86bn, equivalent to €28.00 per share. The members of the Recordati family will receive part of the consideration in the form of a deferred and subordinated long-term debt security in the amount of €750 million. Furthermore, Andrea Recordati in his capacity as CEO will invest alongside the Consortium.

Closing of the FIMEI purchase is anticipated to take place in the last quarter of 2018 and is subject only to mandatory competition approvals. Following closing, in accordance with CONSOB rules, the Consortium will make a mandatory tender offer (“MTO”) to the remaining minority shareholders. The Consortium’s current expectation is that Recordati will remain a publicly listed company. The Recordati family requested, and the Consortium has agreed, to provide other shareholders with a full cash offer at €28.00 per share, which implies a higher economic value than the cash and deferred payment made to the Recordati family. The offer of the full price in cash to the minority shareholders in the MTO is subject to the absence of a material market correction prior to closing of the FIMEI transaction (defined as a decrease in the FTSE MIB index of more than 20%). In such an event, the Consortium intends to lower the cash offer price in the MTO, in consultation and agreement with CONSOB, to a price equivalent to the actual consideration paid to the Recordati family (taking into account the present value of the deferred payment).

Leopoldo Zambeletti and Rothschild are acting as financial advisor to CVC. Gattai, Minoli, Agostinelli & Partners together with White & Case LLP are acting as legal advisors to CVC. Facchini, Rossi are acting as tax advisor to CVC. Committed financing for the transaction is being provided by Deutsche Bank, Credit Suisse, Jefferies and Unicredit.

The Consortium led by CVC Fund VII includes PSP Investments and StepStone.

Categories: News


Gimv and Mérieux Développement accelerate the expansion of SGH Healthcaring – Stiplastics’ parent company embarks on its first external growth deals with the acquisition of Rovipharm and RR Plastiques


20/06/2018 – 18:00 | Portfolio

Antwerp / Lyon / Saint-Marcellin, 20 June 2018, 6:00pm

Just six months after having acquired Stiplastics Healthcaring and setting up the SGH Healthcaring Group, Gimv and Mérieux Développement are pleased to announce the acquisition by SGH Healthcaring of French companies Rovipharm and RR Plastiques. These first acquisitions will enable the Group to take on a new dimension, doubling in size, and to complete its product range thanks to the complementary fit of their product portfolios.

SGH Healthcaring designs, develops and manufactures standard and smart plastic solutions for the pharmaceutical industries and the health sector. The Group structures its activities around two strategic areas:

  • specific developments of devices in four main areas: the observance and administration of medication, respiratory devices, pre-analytics and e-health with IoC® [Internet of Care],
  • a standard range of medical devices for the dosage and administration of medication.

Rovipharm and RR Plastiques bring their know-how in this second area, bolstering SGH Healthcaring’s portfolio of dispensers for medication in liquid form. Rovipharm is a leader in Europe in medication dosage pipettes. It stands out due to its capacity to develop high-quality products in cleanrooms at a competitive cost. RR Plastiques is a leading player in droppers to dispense ear and eye care solutions and will notably bring to the table its capacity to use various specific materials (Sebs, Eva, Santoprène®, plasticised PVC, etc.). As part of this transaction, Médicos is retaining RR Plastiques’ minor applications for the cosmetic industry.

When they made their joint investment in Stiplastics Healthcaring in January 2018, Gimv and Mérieux Développement wanted to create a European leader in the manufacture of medical devices, notably for the administration of medication in both liquid and solid form. This objective hinged on a buy & build roadmap that was carefully thought out well ahead of the acquisition. This preparation and the active support of the Group’s shareholders – notably through discussions with the sellers – facilitated the rapid implementation of SGH Healthcaring’s external growth strategy with as goal to establish a market leader in its sector.

While Gimv and Mérieux Développement had opted to make their initial investment in Stiplastics Healthcaring without LBO financing, this double acquisition was done in parallel with a refinancing process that puts SGH Healthcaring in perfect stead to pursue its buy & build strategy. Its solid shareholders and a financing package that has been put together by Bluebay will help to fulfil its ambitions.

“We are very proud to welcome these two established companies and their talented people to SGH Healthcaring, where they will join us in our ambitious plan to expand in a consolidating market. These first deals lift our turnover up to approximately EUR 40 million for 2018. These acquisitions and the external financing put in place provide a firm basis for SGH Healthcaring to pursue its development strategy” explained Benoit Chastaing, Partner Health & Care at Gimv.

“Less than six months after investing in Stiplastics Healthcaring, we are very pleased to achieve this first major milestone in the roadmap that we have put together with the management team of Stiplastics Healthcaring to form a large group that can meet the increasing demands of the healthcare industry” said Jean-François Billet, Senior Partner at Mérieux Développement.

“When the ownership structure was changed, we clearly expressed our ambition to create a European leader in medical devices, amid increasingly-stringent regulatory constraints and greater demands from clients. These two acquisitions mark a first step in our ambitious growth” added Jérôme Empereur, Chairman and Chief Executive Officer at SGH Healthcaring.

The financial details of the transactions will not be disclosed.

Categories: News


AAC Capital takes over shares in Fysius Back Clinics from Gilde Healthcare

GIlde Healthcare

Gilde Healthcare has announced that they have transferred their shares in the physiotherapy chain Fysius Back Clinics to AAC Capital. With the support of Gilde Healthcare, Fysius has grown into a national chain with 29 locations specialized in back care.

Fysius is a chain of treatment centers specializing in the treatment of back, neck and pelvic complaints. The company stands out for its science-based treatment protocol performed by specialized physiotherapists with personal treatment plans and specialist treatment equipment. Gilde Healthcare has worked with Fysius since 2011, when Fysius had 13 branches and was looking for growth capital to expand on a national level. Together with the management, Gilde developed the company into the largest specialist physiotherapy provider, with 29 branches and over 175 employees.

IT has played a significant role in the growth of Fysius. “We are one of the first primary healthcare providers to operate entirely digitally and use modern analysis techniques to continually improve healthcare for our customers,” says Eline Termaat, CEO of Fysius. “Each year, we treat over 35,000 clients and analyze this data in order to improve our protocols and service provision as well. This helps us to provide demonstrably better healthcare for lower back-related pain, which is what our customers are looking for.”

The collaboration between Gilde Healthcare and Fysius has run according to plan. “We have successfully implemented the transformation into a specialist physiotherapy chain with a science-based treatment protocol in back care. Now is a good time for Gilde to pass on the baton. Fysius is ready for the next growth phase,” says Hugo de Bruin, partner at Gilde Healthcare.

Maurice Bronckers, Managing Partner at AAC Capital, says: “We are delighted to have the opportunity to invest in Fysius in collaboration with Eline Termaat. Fysius really have proved themselves as a specialist in the treatment of back complaints in the Netherlands. We are looking forward to working together with Eline and the rest of her management team to enable Fysius to grow further.”

Categories: News


Envision Healthcare to be Acquired by KKR for $46.00 Per Share in All-Cash Transaction


NASHVILLE, Tenn.–(BUSINESS WIRE)– Envision Healthcare Corporation (“Envision” or the “Company”) (NYSE: EVHC) today announced it has entered into a definitive agreement to be acquired by global investment firm KKR in an all-cash transaction for approximately $9.9 billion, including the assumption or repayment of debt. Under the terms of the agreement, which has been unanimously approved by Envision’s Board of Directors (the “Board”), KKR will acquire all of the outstanding shares of Envision’s common stock for $46.00 per share in cash, representing a 32% premium to Envision’s volume-weighted average share price (VWAP) from November 1, 2017, the day immediately following the Company’s first announcement that it was reviewing strategic alternatives. The transaction price represents a multiple of 10.9x trailing 12 months Adjusted EBITDA and 10.1x 2018 anticipated Adjusted EBITDA.1

This press release features multimedia. View the full release here:

The agreement represents the culmination of the Board’s comprehensive review of strategic alternatives to enhance shareholder value. During the last seven months, the Board, with the assistance of three independent financial advisors and legal counsel, examined a full range of options to generate shareholder value, including capital structure alternatives, potential acquisitions, portfolio optimization, a potential sale of the whole company, and continued operation as a standalone business. The Board oversaw an extensive process that involved outreach to 25 potential buyers, including financial sponsors and strategic entities, and invited proposals for all or parts of the business. After consideration of the opportunities, risks and uncertainties facing the Company and the broader sector, as well as the alternatives available to the Company, the Board determined that the KKR proposal presented the best opportunity to maximize value for shareholders.

James D. Shelton, Envision’s Lead Independent Director, commented, “After conducting a robust review of the business and competitive landscape, the Company’s opportunities and challenges, and the strategic and financial alternatives available to the Company, the Board unanimously believes that this transaction will deliver the most value to Envision’s shareholders.”

Christopher A. Holden, Envision’s President, Chief Executive Officer and Director, added, “Envision’s leadership team – including both the Board and management – have been singularly focused on driving value for our shareholders and have taken decisive action in furtherance of that goal, including the implementation of a comprehensive operational improvement plan and a robust review of strategic alternatives. Today’s announcement reflects the extensive efforts by our team to explore all opportunities to deliver value for our shareholders.”

“Envision is a leading provider of physician-led services in a health care system in which physician-patient interactions have a pronounced impact on nearly all health care decisions. Envision has a very strong reputation for delivering high-quality, patient-focused care through its network of 25,000 clinical professionals at thousands of hospitals, surgery centers and alternate sites of care across the country,” said Jim Momtazee, Head of KKR’s Health Care investment team. “We are excited to partner with the outstanding team led by Chris Holden to help build upon the strong foundation in place and accelerate Envision’s growth going forward.”

The completion of the transaction, which is targeted for the fourth quarter of 2018, is subject to customary closing conditions and regulatory approvals. Envision intends to present the proposed transaction to its shareholders for approval at the Company’s 2018 Annual Meeting, which will be scheduled as soon as practicable following the filing and review of proxy materials. The Company intends to hold its Annual Meeting no later than October 1, 2018. Upon the completion of the transaction, Envision will become a private company, and its common stock will no longer be traded on the New York Stock Exchange.

KKR will be making the investment primarily from its KKR Americas Fund XII.

J.P. Morgan Securities LLC, Evercore and Guggenheim Securities LLC are serving as financial advisors and Wachtell, Lipton, Rosen & Katz and Bass, Berry & Sims are serving as legal counsel to Envision. Simpson Thacher & Bartlett LLP is acting as legal counsel to KKR. Fully committed debt financing for the transaction will be provided by Citigroup Global Markets, Credit Suisse, Morgan Stanley, Barclays, Goldman Sachs, Jefferies, UBS Investment Bank, RBC Capital Markets, HSBC, Mizuho, and KKR Capital Markets.

About Envision Healthcare Corporation

Envision Healthcare Corporation is a leading provider of physician-led services and post-acute care, and ambulatory surgery services. At March 31, 2018, we delivered physician services, primarily in the areas of emergency department and hospitalist services, anesthesiology services, radiology/tele-radiology services, and children’s services to more than 1,800 clinical departments in healthcare facilities in 45 states and the District of Columbia. Post-acute care is delivered through an array of clinical professionals and integrated technologies which, when combined, contribute to efficient and effective population health management strategies. The Company owns and operates 261 surgery centers and one surgical hospital in 35 states and the District of Columbia, with medical specialties ranging from gastroenterology to ophthalmology and orthopedics. In total, the Company offers a differentiated suite of clinical solutions on a national scale, creating value for health systems, payors, providers and patients. For additional information, visit

About KKR

KKR is a leading global investment firm that manages multiple alternative asset classes, including private equity, growth equity, energy, infrastructure, real estate and credit, with strategic manager partnerships that manage hedge funds. KKR aims to generate attractive investment returns for its fund investors by following a patient and disciplined investment approach, employing world-class people, and driving growth and value creation with KKR portfolio companies. KKR invests its own capital alongside the capital it manages for fund investors and provides financing solutions and investment opportunities through its capital markets business. References to KKR’s investments may include the activities of its sponsored funds. For additional information about KKR & Co. L.P. (NYSE: KKR), please visit KKR’s website at and on Twitter @KKR_Co.

Additional Information and Where to Find It

This communication relates to the proposed merger transaction involving the Company. In connection with the proposed merger, the Company will file relevant materials with the U.S. Securities and Exchange Commission (the “SEC”), including the Company’s proxy statement on Schedule 14A and accompanying definitive WHITE proxy card (the “Proxy Statement”). This communication is not a substitute for the Proxy Statement or any other document that the Company may file with the SEC or send to its stockholders in connection with the proposed merger. BEFORE MAKING ANY VOTING DECISION, STOCKHOLDERS OF THE COMPANY ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING THE PROXY STATEMENT, WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain the documents (when available) free of charge at the SEC’s website,, and the Company’s website,

Participants in the Solicitation

The Company and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the holders of Company common stock in respect of the proposed transaction. Information about the directors and executive officers of the Company is set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on March 1, 2018, as amended by the Company’s Annual Report on Form 10-K/A filed with the SEC on April 30, 2018. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the Proxy Statement and other relevant materials to be filed with the SEC in respect of the proposed transaction.

Forward-Looking Statements

Certain statements and information in this communication may be deemed to be “forward-looking statements” within the meaning of the Federal Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to the proposed transaction, the Company’s financial and operating objectives, plans and strategies, industry trends, and all statements (other than statements of historical fact) that address activities, events or developments that the Company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions, and are based on assumptions and assessments made by the Company’s management in light of their experience and their perception of historical trends, current conditions, expected future developments, and other factors they believe to be appropriate. Any forward-looking statements in this communication are made as of the date hereof, and the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance. Whether actual results will conform to expectations and predictions is subject to known and unknown risks and uncertainties, including: (i) risks and uncertainties discussed in the reports and other documents that the Company files with the SEC; (ii) risks related to the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement; (iii) the failure to obtain Company stockholder approval of the transaction or required regulatory approvals or the failure to satisfy any of the other conditions to the completion of the transaction; (iv) the effect of the announcement of the transaction on the ability of the Company to retain and hire key personnel and maintain relationships with its customers, suppliers, partners and others with whom it does business, or on its operating results and businesses generally; (v) risks associated with the disruption of management’s attention from ongoing business operations due to the transaction; (vi) the ability to meet expectations regarding the timing and completion of the transaction; (vii) general economic, market, or business conditions; (viii) the impact of legislative or regulatory changes, such as changes to the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010; (ix) changes in governmental reimbursement programs; (x) decreases in revenue and profit margin under fee-for-service contracts due to changes in volume, payor mix and reimbursement rates; (xi) the loss of existing contracts; and (xii) other circumstances beyond the Company’s control.

1 As of 3/31/2018. 2018E EBITDA multiple based on midpoint of Company guidance

Envision Healthcare Corporation
Bob Kneeley, 303-495-1245
Vice President, Investor Relations
Sard Verbinnen & Co
Jared Levy, 212-687-8080
Jacob Crows, 212-687-8080
Warren Rizzi, 212-687-8080
Kristi Huller, 212-750-8300
Cara Major, 212-750-8300

Source: Envision Healthcare Corporation

News Provided by Acquire Media

Categories: News


EQT Credit provides financing to support the acquisition of Biovian


EQT Credit, through its Mid-Market investment strategy, is pleased to announce that it has provided the financing to support Keensight Capital and ERES’ (the “Shareholders”) investment in Biovian (or the “Company”), a leading European player in contract manufacturing and development of biopharmaceuticals. The Company offers outsourcing services in process development and contract manufacturing for small and medium size biotechnology firms and has deep industry expertise across different key biological processes.

Founded in 2003 and based in Turku, Finland, Biovian has 70 employees and a strong offering in key stages of the drug development lifecycle. With main operations in UK, EU, US and South Korea, the Company benefits from a strong Biotech pipeline, fueled by new biologic products progressively replacing traditional pharma.

EQT Credit, as sole lender, is providing a unitranche facility to back the Shareholders acquisition of Biovian.

Paul Johnson, Partner at EQT Partners’ Credit team, Investment Advisor to EQT Credit, commented: ”Biovian has a stable business model and a strong backlog supported by its entrenched relationships with customers. EQT Credit is pleased to provide a financing solution for Biovian and look forward to supporting the Company and its management team under the Shareholders new ownership”.

Paul Johnson, Partner at EQT Partners, Investment Advisor to EQT Mid-Market Credit, +44 203 372 94 24
Alexandre Hökfelt, Director at EQT Partners, Investment Advisor to EQT Mid-Market Credit, +44 203 372 94 14
EQT Press Office, +46 8 506 55 334,

About EQT Credit
EQT Credit invests through three complementary strategies: Senior Debt, Mid-Market Credit (direct lending) and Credit Opportunities. Since inception, EQT Credit has invested in excess of EUR 5 billion in over 160 companies. EQT Credit’s direct lending strategy seeks to provide flexible, long-term debt capital solutions to medium-sized European businesses, across a wide range of sectors. These businesses may be privately-owned corporates seeking alternative funding to grow or be the subject of private equity-led acquisitions or refinancings.

More info:

About EQT
EQT is a leading alternative investments firm with approximately EUR 50 billion in raised capital across 27 funds. EQT funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 19 billion and approximately 110,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership.

More information:

Categories: News


IK Investment Partners acquires KLINGEL medical metal


IK Investment Partners (“IK”) is pleased to announce that the IK VIII Fund has reached an agreement to acquire Klingel medical metal GmbH (“KLINGEL” or “the Company”), a leading manufacturer of high-precision and complex metal components mainly for a range of medical technology applications, from Halder. 

KLINGEL was established in 1986 and has become a leading independent contract manufacturer of high-precision, hard-to-machine parts made from titanium and high-grade types of stainless steel. The Company operates a vertically integrated business model with in-house capabilities spanning the entire production value chain from design to manufacture to final packaging with a strategic focus on medical technology. KLINGEL’s high precision components go into various orthopaedic, cardiovascular and dental implants as well as instruments for endoscopy and robotic surgery.

Working in partnership with its OEM customers across the medical technology as well as measurement and control industries, KLINGEL has gained a reputation for uncompromising quality. Headquartered in Pforzheim, Germany, the Company operates two manufacturing sites with over 200 CNC machines and employs more than 300 people.

“By providing mission critical components of the highest quality standards, KLINGEL has formed long-standing relationships with our customers. IK has a genuine understanding of the CMO market and shares our international growth strategy. With their support, we will continue contributing to our customers’ success by offering real added value to their end consumers,” said Ralf Petrawitz, Technical and Commercial Managing Director of KLINGEL.

“We are impressed by KLINGEL’s strong management team. Together we will continue to build on the strong market position, technical know-how and broad service offering KLINGEL has developed over the last three decades. IK is well-positioned to support KLINGEL thanks to our experience with Marle, a leading European CMO of hip and knee orthopaedic implants, acquired in 2016,” says Anders Petersson, Partner at IK.

KLINGEL represents the IK VIII Fund’s second mid cap acquisition in the past month, and the 11th acquisition announced by the Fund. Financial terms of the transaction are not disclosed.

Parties involved:

IK Investment Partners: Anders Petersson, Mirko Jablonsky, Alexander Dokters, Adrian Tanski, Daniel-Vito Günther
Buyer financial advisor: Quarton International (Lars Veit, Rolf Holtmann)
Buyer strategic due diligence: Alvarez & Marsal (Georg Hochleitner)
Buyer financial due diligence: Ebner Stolz (Claus Bähre)
Buyer legal advisor: Renzenbrink & Partner (Ulf Renzenbrink)

Halder: Michael Wahl, Christian Muschalik
Seller financial advisor: William Blair (Philipp Mohr, Moritz Rottwinkel)
Seller legal advisor: Graf von Westfalen (Lutz Zimmer, Ernst Lindl)

For further questions, please contact:

KLINGEL medical metal
Ralf Petrawitz, Managing Director
Phone: +49 7231 6519 0

IK Investment Partners
Anders Petersson, Partner
Phone: +49 40 369 8850

Mikaela Hedborg, Director Communications & ESG
Phone: +44 77 87 573 566

About KLINGEL medical metal
For more than 30 years, KLINGEL medical metal GmbH has been one of the leading European precision technology companies with a strategic focus on medical technology industries. Employing over 300 people, KLINGEL medical metal GmbH specialises in the precision processing of materials with low machinability, such as titanium and high-grade stainless steel. KLINGEL offers unrivalled technical quality and aesthetic perfection. For more information, visit

About IK Investment Partners
IK Investment Partners (“IK”) is a Pan-European private equity firm focused on investments in the Nordics, DACH region, France, and Benelux. Since 1989, IK has raised more than €9.5 billion of capital and invested in over 115 European companies. IK funds support companies with strong underlying potential, partnering with management teams and investors to create robust, well-positioned businesses with excellent long-term prospects. For more information, visit

Categories: News